312 related articles for article (PubMed ID: 25369529)
1. YAP/TEAD co-activator regulated pluripotency and chemoresistance in ovarian cancer initiated cells.
Xia Y; Zhang YL; Yu C; Chang T; Fan HY
PLoS One; 2014; 9(11):e109575. PubMed ID: 25369529
[TBL] [Abstract][Full Text] [Related]
2. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
[TBL] [Abstract][Full Text] [Related]
3. Targeting YAP in malignant pleural mesothelioma.
Zhang WQ; Dai YY; Hsu PC; Wang H; Cheng L; Yang YL; Wang YC; Xu ZD; Liu S; Chan G; Hu B; Li H; Jablons DM; You L
J Cell Mol Med; 2017 Nov; 21(11):2663-2676. PubMed ID: 28470935
[TBL] [Abstract][Full Text] [Related]
4. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
Lee BS; Park DI; Lee DH; Lee JE; Yeo MK; Park YH; Lim DS; Choi W; Lee DH; Yoo G; Kim HB; Kang D; Moon JY; Jung SS; Kim JO; Cho SY; Park HS; Chung C
Biochem Biophys Res Commun; 2017 Sep; 491(2):493-499. PubMed ID: 28684311
[TBL] [Abstract][Full Text] [Related]
5. Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex.
Wei H; Wang F; Wang Y; Li T; Xiu P; Zhong J; Sun X; Li J
Cancer Sci; 2017 Mar; 108(3):478-487. PubMed ID: 28002618
[TBL] [Abstract][Full Text] [Related]
6. Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway.
Mo JS; Meng Z; Kim YC; Park HW; Hansen CG; Kim S; Lim DS; Guan KL
Nat Cell Biol; 2015 Apr; 17(4):500-10. PubMed ID: 25751140
[TBL] [Abstract][Full Text] [Related]
7. Verteporfin inhibits growth of human glioma in vitro without light activation.
Al-Moujahed A; Brodowska K; Stryjewski TP; Efstathiou NE; Vasilikos I; Cichy J; Miller JW; Gragoudas E; Vavvas DG
Sci Rep; 2017 Aug; 7(1):7602. PubMed ID: 28790340
[TBL] [Abstract][Full Text] [Related]
8. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation.
Lin KC; Moroishi T; Meng Z; Jeong HS; Plouffe SW; Sekido Y; Han J; Park HW; Guan KL
Nat Cell Biol; 2017 Jul; 19(8):996-1002. PubMed ID: 28752853
[TBL] [Abstract][Full Text] [Related]
9. The TEAD Family and Its Oncogenic Role in Promoting Tumorigenesis.
Zhou Y; Huang T; Cheng AS; Yu J; Kang W; To KF
Int J Mol Sci; 2016 Jan; 17(1):. PubMed ID: 26805820
[TBL] [Abstract][Full Text] [Related]
10. TEAD mediates YAP-dependent gene induction and growth control.
Zhao B; Ye X; Yu J; Li L; Li W; Li S; Yu J; Lin JD; Wang CY; Chinnaiyan AM; Lai ZC; Guan KL
Genes Dev; 2008 Jul; 22(14):1962-71. PubMed ID: 18579750
[TBL] [Abstract][Full Text] [Related]
11. Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides.
Zhou Z; Hu T; Xu Z; Lin Z; Zhang Z; Feng T; Zhu L; Rong Y; Shen H; Luk JM; Zhang X; Qin N
FASEB J; 2015 Feb; 29(2):724-32. PubMed ID: 25384421
[TBL] [Abstract][Full Text] [Related]
12. Loss of DLG5 promotes breast cancer malignancy by inhibiting the Hippo signaling pathway.
Liu J; Li J; Li P; Wang Y; Liang Z; Jiang Y; Li J; Feng C; Wang R; Chen H; Zhou C; Zhang J; Yang J; Liu P
Sci Rep; 2017 Feb; 7():42125. PubMed ID: 28169360
[TBL] [Abstract][Full Text] [Related]
13. A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ.
Tan G; Cao X; Dai Q; Zhang B; Huang J; Xiong S; Zhang Yy; Chen W; Yang J; Li H
Oncotarget; 2015 Apr; 6(11):8676-86. PubMed ID: 25895125
[TBL] [Abstract][Full Text] [Related]
14. TFCP2 Is Required for YAP-Dependent Transcription to Stimulate Liver Malignancy.
Zhang X; Sun F; Qiao Y; Zheng W; Liu Y; Chen Y; Wu Q; Liu X; Zhu G; Chen Y; Yu Y; Pan Q; Wang J
Cell Rep; 2017 Oct; 21(5):1227-1239. PubMed ID: 29091762
[TBL] [Abstract][Full Text] [Related]
15. YAP/TAZ enhance mammalian embryonic neural stem cell characteristics in a Tead-dependent manner.
Han D; Byun SH; Park S; Kim J; Kim I; Ha S; Kwon M; Yoon K
Biochem Biophys Res Commun; 2015 Feb; 458(1):110-6. PubMed ID: 25634692
[TBL] [Abstract][Full Text] [Related]
16. Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance.
Wang DY; Wu YN; Huang JQ; Wang W; Xu M; Jia JP; Han G; Mao BB; Bi WZ
Chin J Cancer; 2016 May; 35():47. PubMed ID: 27206784
[TBL] [Abstract][Full Text] [Related]
17. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy.
Pobbati AV; Hong W
Theranostics; 2020; 10(8):3622-3635. PubMed ID: 32206112
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
Chen M; Wang M; Xu S; Guo X; Jiang J
Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
[TBL] [Abstract][Full Text] [Related]
19. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity.
Shimomura T; Miyamura N; Hata S; Miura R; Hirayama J; Nishina H
Biochem Biophys Res Commun; 2014 Jan; 443(3):917-23. PubMed ID: 24380865
[TBL] [Abstract][Full Text] [Related]
20. YAP/TEAD-mediated transcription controls cellular senescence.
Xie Q; Chen J; Feng H; Peng S; Adams U; Bai Y; Huang L; Li J; Huang J; Meng S; Yuan Z
Cancer Res; 2013 Jun; 73(12):3615-24. PubMed ID: 23576552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
